Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors

Table 1 Relapse rate in non-systemic JIA patients after withdrawal of bDMARD

Main author	Anink	Giménez- Roca	Lovell	Leong	Aquilani	Chang			Hissink Muller	Prince	Foeldvari	Iglesias	Windschall	Southwood	Otten
[Ref]	[18]	[21]	[22]	[23]	[24]	[25]			[26]	[27]	[28]	[29]	[19]	[30]	[31]
n=	26	6	106	20	110	25^e	17^f	7^g	19	14	22	18	24	5	6
Medication type	Etanercept	Etanercept	Etanercept	Etanercept	Etanercept	Etanercept			Etanercept	Etanercept	Etanercept	Etanercept	Etanercept	Etanercept	Etanercept
		Adalimumab	Adalimumab	Adalimumab		Adalimumab						Adalimumab
			Infliximab	Infliximab		Infliximab						Infliximab
Time in inactive disease, months	at least 6	12	at least 6	at least 6		unknown					unknown		at least 18^j	unknown	unknown^k
mean (range)									5.8 (3-6)	8 (0-35)		12.2^h
median (range)					14.6^c
Follow up duration, months	6	7	8	8	12	at least 6			unknown	unknown	unknown	unknown	unknown	unknown	unknown
% relapse after withdrawal	46.2%	100%	36.8%	45%	60%	78%^e	76%^f	78%^g	26.3%	57.1%	59.1%	77.80%	50%	60%	83.3%
Time to relapse, months
mean (range)			7^a									3.0ⁱ	8.4 (4-72)		2 (0,7-10)
median (range)			8.3^b		4.3^d				3 (3-7.5)	2,6 (0,4-27)	7			10 (5-34)
% relapse after 6 months	46.2%				40%	47%^e	48%^f	31%^g
% relapse after 7 months		100%
% relapse after 8 months			36.8%	45%
% relapse after 12 months					60%	78%^e	76%^f	78%^g

ISSN: 1546-0096